Bernstein on Intellia Therapeutics (NTLA): 'Investor Perception Takes Another Big Hit'
Tweet Send to a Friend
Bernstein SocGen Group analyst William Pickering reiterated an Outperform rating and $45.00 price target on Intellia Therapeutics (NASDAQ: NTLA).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
